The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That Matters

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Sep 28

PMID 34571965

Citations 7

Authors

Lucia Catani

Michele Cavo

Francesca Palandri

Affiliations

Soon will be listed here.

Abstract

Myeloproliferative Neoplasms (MPN) are acquired clonal disorders of the hematopoietic stem cells and include Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis. MPN are characterized by mutations in three driver genes ( and ) and by a state of chronic inflammation. Notably, MPN patients experience increased risk of thrombosis, disease progression, second neoplasia and evolution to acute leukemia. Extracellular vesicles (EVs) are a heterogeneous population of microparticles with a role in cell-cell communication. The EV-mediated cross-talk occurs via the trafficking of bioactive molecules such as nucleic acids, proteins, metabolites and lipids. Growing interest is focused on EVs and their potential impact on the regulation of blood cancers. Overall, EVs have been suggested to orchestrate the complex interplay between tumor cells and the microenvironment with a pivotal role in "education" and "crafting" of the microenvironment by regulating angiogenesis, coagulation, immune escape and drug resistance of tumors. This review is focused on the role of EVs in MPN. Specifically, we will provide an overview of recent findings on the involvement of EVs in MPN pathogenesis and discuss opportunities for their potential application as diagnostic and prognostic biomarkers.

Citing Articles

TNF-α is a predictive marker in distinguishing myeloproliferative neoplasm and idiopathic erythrocytosis/thrombocytosis: development and validation of a non-invasive diagnostic model.

Wang Z, Mei Y, Yang Z, Gao Q, Xu H, Han Z Front Oncol. 2024; 14:1369346.

PMID: 38585007 PMC: 10995358. DOI: 10.3389/fonc.2024.1369346.

Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them?.

Morales M, Ferrer-Marin F Cancers (Basel). 2023; 15(4).

PMID: 36831689 PMC: 9954305. DOI: 10.3390/cancers15041348.

Extracellular Vesicles in Haematological Disorders: A Friend or a Foe?.

Lazana I Int J Mol Sci. 2022; 23(17).

PMID: 36077514 PMC: 9455998. DOI: 10.3390/ijms231710118.

Extracellular Vesicles in Myeloid Neoplasms.

Karantanou C, Minciacchi V, Karantanos T Int J Mol Sci. 2022; 23(15).

PMID: 35955960 PMC: 9369333. DOI: 10.3390/ijms23158827.

Blood Cell-Derived Microvesicles in Hematological Diseases and beyond.

Georgatzakou H, Fortis S, Papageorgiou E, Antonelou M, Kriebardis A Biomolecules. 2022; 12(6).

PMID: 35740926 PMC: 9220817. DOI: 10.3390/biom12060803.

References

Elliott M, Verstovsek S, Dingli D, Schwager S, Mesa R, Li C . Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007; 31(11):1503-9. DOI: 10.1016/j.leukres.2006.12.025. View

Barraco D, Cerquozzi S, Gangat N, Patnaik M, Lasho T, Finke C . Monocytosis in polycythemia vera: Clinical and molecular correlates. Am J Hematol. 2017; 92(7):640-645. DOI: 10.1002/ajh.24740. View

Schafer A . Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2021; 35(2):305-324. DOI: 10.1016/j.hoc.2020.11.006. View

Koga K, Matsumoto K, Akiyoshi T, Kubo M, Yamanaka N, Tasaki A . Purification, characterization and biological significance of tumor-derived exosomes. Anticancer Res. 2005; 25(6A):3703-7. View

Brabrand M, Frederiksen H . Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications. Cancers (Basel). 2020; 12(10). PMC: 7589412. DOI: 10.3390/cancers12103061. View

Taniguchi Y, Tanaka H, Luis E, Sakai K, Kumode T, Sano K . Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms. Int J Hematol. 2017; 106(5):691-703. DOI: 10.1007/s12185-017-2302-5. View

Karantanos T, Jain T, Moliterno A, Jones R, DeZern A . Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology. Int J Mol Sci. 2021; 22(5). PMC: 7961949. DOI: 10.3390/ijms22052595. View

Pezzicoli G, Tucci M, Lovero D, Silvestris F, Porta C, Mannavola F . Large Extracellular Vesicles-A New Frontier of Liquid Biopsy in Oncology. Int J Mol Sci. 2020; 21(18). PMC: 7555129. DOI: 10.3390/ijms21186543. View

Vagner T, Spinelli C, Minciacchi V, Balaj L, Zandian M, Conley A . Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. J Extracell Vesicles. 2018; 7(1):1505403. PMC: 6084494. DOI: 10.1080/20013078.2018.1505403. View

10.

Koschmieder S, Mughal T, Hasselbalch H, Barosi G, Valent P, Kiladjian J . Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016; 30(5):1018-24. DOI: 10.1038/leu.2016.12. View

11.

Alzhrani G, Alanazi S, Alsharif S, Albalawi A, Alsharif A, Abdel-Maksoud M . Exosomes: Isolation, characterization, and biomedical applications. Cell Biol Int. 2021; 45(9):1807-1831. DOI: 10.1002/cbin.11620. View

12.

Latifkar A, Hur Y, Sanchez J, Cerione R, Antonyak M . New insights into extracellular vesicle biogenesis and function. J Cell Sci. 2019; 132(13). PMC: 6633391. DOI: 10.1242/jcs.222406. View

13.

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

14.

Duchemin J, Ugo V, Ianotto J, Lecucq L, Mercier B, Abgrall J . Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res. 2010; 126(3):238-42. DOI: 10.1016/j.thromres.2010.06.025. View

15.

Tan X, Shi J, Fu Y, Gao C, Yang X, Li J . Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. Thromb Haemost. 2013; 109(6):1025-32. DOI: 10.1160/TH12-11-0811. View

16.

Briard D, Brouty-Boye D, Giron-Michel J, Azzarone B, Jasmin C, Le Bousse-Kerdiles C . Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis. Clin Immunol. 2003; 106(3):201-12. DOI: 10.1016/s1521-6616(02)00046-3. View

17.

Donoso-Quezada J, Ayala-Mar S, Gonzalez-Valdez J . The role of lipids in exosome biology and intercellular communication: Function, analytics and applications. Traffic. 2021; 22(7):204-220. PMC: 8361711. DOI: 10.1111/tra.12803. View

18.

Tefferi A, Barbui T . Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018; 94(1):133-143. DOI: 10.1002/ajh.25303. View

19.

Corbeil D, Santos M, Karbanova J, Kurth T, Rappa G, Lorico A . Uptake and Fate of Extracellular Membrane Vesicles: Nucleoplasmic Reticulum-Associated Late Endosomes as a New Gate to Intercellular Communication. Cells. 2020; 9(9). PMC: 7563309. DOI: 10.3390/cells9091931. View

20.

Gersuk G, Carmel R, Pattamakom S, Challita P, Rabinowitz A, Pattengale P . Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity. Nat Immun. 1993; 12(3):136-51. View